We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combined Serology and Genotyping Reduces False Positive Diagnosis of Celiac Disease

By LabMedica International staff writers
Posted on 09 Sep 2013
A new diagnostic approach for detection of celiac disease (CD) that combines genomic assessment and serology revealed that this immune disorder is far more common in the Australian population than previously thought but was often diagnosed incorrectly.

Investigators at the Walter and Eliza Hall Institute (Victoria, Australia) and their colleagues combined traditional antibody testing for CD (measuring the immune response to gluten) with an assessment of specific genetic risk markers.

They evaluated serum samples from 356 patients with biopsy-confirmed CD, and from two age-stratified, randomly selected community cohorts of 1,390 women and 1,158 men. More...
The samples were tested for antigluten antibodies by standard serological techniques and (HLA)-DQ genotyping was performed using Taqman SNP genotyping methods (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s protocols.

Results revealed that celiac disease potentially affected at least one in 60 Australian women and one in 80 men. Previous estimates had suggested that the number of Australians with celiac disease was no more than 1%. Furthermore, serogenetic data indicated that testing screen positives for HLA-DQ, or carrying out HLA-DQ and further serology, could have reduced unnecessary gastroscopies due to false-positive serology by at least 40% and by over 70%, respectively.

“Currently, bowel biopsies are recommended for anybody with positive antibody tests,” said contributing author Dr. Jason Tye-Din, a gastroenterologist at the Walter and Eliza Hall Institute. “In this study, the inclusion of a simple genetic test helped identify a substantial number of people whose antibody tests were falsely positive and who did not actually require a bowel biopsy to test for the possibility of celiac disease.”

“It is concerning that a significant number of people in the community with celiac disease have not been diagnosed,” said Dr. Tye-Din. “Accurate and timely diagnosis is important for the health of patients with celiac disease. Making a diagnosis based on a blood test alone or commencing a gluten-free diet without a confirmatory bowel biopsy is inappropriate and can impose an unnecessary and lifelong treatment. Although small bowel biopsy is needed to confirm celiac disease, it is costly and invasive. Reducing unnecessary procedures is better for patients, eliminating an invasive test, and better for the economy by reducing healthcare costs. This study provides a strategy to improve the diagnosis of celiac disease in the community by combining the benefits of antibody and genetic testing.”

Related Links:
Applied Biosystems
Walter and Eliza Hall Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.